Lifescience
Implantable Cardioverter Defibrillator Market Estimated to Grow at a CAGR of 4.1% During Forecast Period 2020-2025
Implantable Cardioverter Defibrillator Market size is estimated to be $7.8 billion in 2019, growing at a CAGR of 4.1% during the forecast period 2020-2025. Implantable Cardioverter Defibrillator devices are implanted in patients who are at high risk for sudden cardiac arrest owing to sustained ventricular tachycardia and are used to improve the heart's pumping ability in heart failure patients. Increasing incidence of cardiovascular diseases and changing lifestyle are the major factors driving the growth of the market. Rising aging population further enhance the overall market demand of Implantable Cardioverter Defibrillator.
Key Takeaways
- North America dominates the Implantable Cardioverter Defibrillator Market in 2019 owing to the increase in consumer awareness about Cardioverter defibrillator. The Implantable Cardioverter Defibrillator Market scope for different regions will be provided in the final report.
- Increasing awareness programs on defibrillator and increasing technological advancements is likely to aid in the market growth of implantable Cardioverter defibrillator.
- Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Implantable Cardioverter Defibrillator Market report.
- Lack of skilled workers and increasing incidence of defibrillator malnutrition among consumers create hurdles for the Implantable Cardioverter Defibrillator Market.
- Increasing awareness programs on defibrillator and increasing technological advancements
- Increasing incidence of cardiovascular diseases and changing lifestyle
- Lack of skilled workers and increasing incidence of defibrillator malnutrition
- In September, 2017 Boston Scientific Corp. launched the Resonate family of implantable cardioverter defibrillator and cardiac resynchronization therapy defibrillator systems.
- In October 2019, Medtronic plc announced the start of a worldwide pivotal study evaluating its investigational Extravascular Implantable Cardioverter Defibrillator system to treat dangerously fast heart rhythms.






